Sebetralstat
HAE - On-demand treatment in pediatric patients (2-11 years)
Key Facts
About KalVista Pharmaceuticals
KalVista Pharmaceuticals is dedicated to advancing oral small molecule medicines for rare diseases with significant unmet needs, with its primary focus on hereditary angioedema (HAE). The company achieved a major milestone with the FDA approval of EKTERLY® (sebetralstat), the first oral on-demand treatment for HAE attacks, which is now commercially launched. Beyond its commercial product, KalVista maintains an innovative pipeline including oral Factor XIIa inhibitors for prophylactic HAE treatment and is exploring applications in thrombosis and inflammation. With over 250 employees worldwide, the company combines scientific expertise with commercial execution to transform patient care.
View full company profileAbout KalVista Pharmaceuticals
KalVista Pharmaceuticals is dedicated to advancing oral small molecule medicines for rare diseases with significant unmet needs, with its primary focus on hereditary angioedema (HAE). The company achieved a major milestone with the FDA approval of EKTERLY® (sebetralstat), the first oral on-demand treatment for HAE attacks, which is now commercially launched. Beyond its commercial product, KalVista maintains an innovative pipeline including oral Factor XIIa inhibitors for prophylactic HAE treatment and is exploring applications in thrombosis and inflammation. With over 250 employees worldwide, the company combines scientific expertise with commercial execution to transform patient care.
View full company profile